News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Victhom Human Bionics (VHB) to List on TSX Venture Exchange and Voluntarly Delist From Toronto Stock Exchange


12/30/2009 11:27:22 AM

QUEBEC, CANADA--(Marketwire - December 30, 2009) - Victhom Human Bionics Inc. ("Victhom" or the "Company") (TSX: VHB) announced today that concurrent to voluntary delisting from the Toronto Stock Exchange, the common shares of the Company will commence trading on the TSX Venture Exchange effective at the opening of trading on December 31, 2009. The Company will be classified as a Tier 1 Technology Issuer on the TSX Venture Exchange. The Company's common shares trading symbol, "VHB", and their CUSIP number, 92581Q502, will remain unchanged.

It is Victhom's view that a listing on the TSX Venture Exchange is appropriate given the current nature of the Company's activities and is consistent with the ongoing process of cost rationalization.

About Victhom

Victhom discovers, develops and manufactures bionic devices involved in the treatment of a variety of physical and physiological dysfunctions. Victhom's wholly owned subsidiary, Victhom Bionized Inc., develops biomechatronic products to support or replace peripheral limbs in what is known as the orthotics and prosthetics market. Victhom also has a 44.4% interest in Neurostream Technologies, General Partnership, a joint venture with Otto Bock HealthCare GmbH, which focuses on the development and commercialization of technologies and products involving devices that feature neurosensing and neurostimulation components, integrated with artificial intelligence.

FORWARD-LOOKING STATEMENTS

Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause Victhom's actual results, performance or achievements to be materially different from those expressed or implied by any of Victhom's statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Contacts:
Victhom Human Bionics Inc.
Normand Rivard
President & CEO
418-872-5665
418-872-6926 (FAX)
normand.rivard@victhom.com
www.victhom.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES